ABSTRACT
General description 1369 Epidemiology 1369 Clinical features 1370 Staging and prognosis 1370 Treatment approaches 1372 General 1372 Skin-directed therapies 1373 Topical corticosteroid therapy 1373 Topical chemotherapy 1373
Topical retinoid therapy 1374 Phototherapy 1374 Radiation therapy 1375 Systemic therapies 1375 Biologic therapies 1376 Systemic chemotherapy 1377 Novel or investigative therapies 1379 Key points 1380 References 1380
Cutaneous T cell lymphomas (CTCL) collectively describe T cell non-Hodgkin lymphomas (NHL) that have primary cutaneous involvement. Mycosis fungoides and Sézary syndrome constitute major subsets of CTCL and are distinct clinical entities from primary cutaneous lymphomas in the new World Health Organization-European Organization for Research and Treatment in Cancer (WHO-EORTC) classification.1 With advances in immunohistochemical and molecular characterization, other distinct clinicopathologic subsets of CTCL have been established.
